Literature DB >> 8570197

MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest.

M C Dubs-Poterszman1, B Tocque, B Wasylyk.   

Abstract

The p53 tumour-suppressor guards the genome in response to genotoxic stress by transcriptional regulation of genes involved in cell-cycle control, DNA replication, repair and apoptosis such as p21, GADD45, bax and mdm2 (Cox and Lane, 1995). Mdm2 is classically considered to be an inhibitor of p53, that forms an auto-regulatory loop (Momand et al., 1992; Oliner et al., 1993; Wu et al., 1993; Chen et al., 1994; Chen and Levine, 1995). It immortalises cells containing wild type p53 and transforms them together with Ras (Finlay, 1993). We show that, in the absence of p53, mdm2 confers a growth advantage to cells (i.e. "transforms" them) and can overcome a G1 cell-cycl arrest induced by p107, a member of the pRb tumour-suppressor family (Adams and Kaelin, 1995). The minimum "transforming" and p107 inhibiting region of Mdm2 corresponds to its p53 binding domain. p53 inhibits transformation by Mdm2, apparently without requiring transcription. p53 can be considered to be a suppressor of Mdm2, a positive effector of the cell cycle. Mdm2 over-expression in tumours is reminiscent of p53 mutations with gain of function, in that Mdm2 both transforms cells and inhibits p53 activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8570197

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

Review 1.  Mdm2: the ups and downs.

Authors:  T Juven-Gershon; M Oren
Journal:  Mol Med       Date:  1999-02       Impact factor: 6.354

2.  MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon.

Authors:  N Vlatkovic; S Guerrera; Y Li; S Linn; D S Haines; M T Boyd
Journal:  Nucleic Acids Res       Date:  2000-09-15       Impact factor: 16.971

3.  Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation.

Authors:  Chiharu Uchida; Seiichi Miwa; Kyoko Kitagawa; Takayuki Hattori; Tomoyasu Isobe; Sunao Otani; Toshiaki Oda; Haruhiko Sugimura; Takehiko Kamijo; Keizou Ookawa; Hideyo Yasuda; Masatoshi Kitagawa
Journal:  EMBO J       Date:  2004-12-02       Impact factor: 11.598

4.  The RING finger domain of MDM2 is essential for MDM2-mediated TGF-beta resistance.

Authors:  Christian Kannemeier; Rong Liao; Peiqing Sun
Journal:  Mol Biol Cell       Date:  2007-04-11       Impact factor: 4.138

5.  The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression.

Authors:  C Venot; M Maratrat; C Dureuil; E Conseiller; L Bracco; L Debussche
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

6.  The Mdm2 oncoprotein interacts with the cell fate regulator Numb.

Authors:  T Juven-Gershon; O Shifman; T Unger; A Elkeles; Y Haupt; M Oren
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

7.  Regulation of the mdm2 oncogene by thyroid hormone receptor.

Authors:  J S Qi; Y Yuan; V Desai-Yajnik; H H Samuels
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

8.  MDM2 controls gene expression independently of p53 in both normal and cancer cells.

Authors:  Giuseppe Arena; Romain Riscal; Laetitia K Linares; Laurent Le Cam
Journal:  Cell Death Differ       Date:  2018-07-23       Impact factor: 15.828

9.  Evidence that the human cytomegalovirus IE2-86 protein binds mdm2 and facilitates mdm2 degradation.

Authors:  Zhigang Zhang; David L Evers; Joseph F McCarville; Jean-Christophe Dantonel; Shu-Mei Huong; Eng-Shang Huang
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.

Authors:  Hongmei Nan; Abrar A Qureshi; David J Hunter; Jiali Han
Journal:  Cancer Causes Control       Date:  2008-09-24       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.